銀屑病是一種遺傳和環(huán)境共同作用誘發(fā)的、免疫介導(dǎo)的慢性炎癥性皮膚病。環(huán)磷酸腺苷(cAMP)/蛋白激酶A(PKA)通路與銀屑病的發(fā)病機(jī)制密切相關(guān),而磷酸二酯酶4是可以專一水解cAMP的酶,因此磷酸二酯酶4成為銀屑病治療的期望小分子靶點(diǎn)。磷酸二酯酶4抑制劑類藥物通過(guò)競(jìng)爭(zhēng)性阻斷磷酸二酯酶4對(duì)cAMP的降解作用,使T輔助細(xì)胞1(Th1)、Th2和Th17的免疫反應(yīng)減弱來(lái)發(fā)揮治療作用。磷酸二酯酶4抑制劑如阿普司特、羅氟司特、克立硼羅、Hemay005、奧利司特、MK-0873、tanimilast、DRM02在治療銀屑病及其共病方面有巨大的潛力。就磷酸二酯酶4抑制劑治療銀屑病的作用機(jī)制、療效、安全性進(jìn)行了總結(jié)。

Psoriasis is an immune-mediated chronic inflammatory skin disease induced by a combination of genetics and the environment. cAMP/PKA pathway is closely related to the pathogenesis of psoriasis, and phosphodiesterase 4 is an enzyme that can specifically hydrolyze cAMP, so phosphodiesterase 4 becomes desired small molecule targets for psoriasis therapy. Phosphodiesterase 4 inhibitor drugs play a therapeutic role by competitively blocking the degradation of cAMP by phosphodiesterase 4, then weakening the immune response of Th1, Th2, and Th-17. Phosphodiesterase 4 inhibitor drugs, such as apremilast, roflumilast, criborrol, Hemay005, orlistat, MK-0873, tanimilast, and DRM02 have great potential in the treatment of psoriasis and its comorbidities. This article summarizes the mechanism of action, efficacy, and safety of phosphodiesterase 4 inhibitor drugs in treatment of psoriasis.

R986